MIRA completes SKNY acquisition, adds three pipeline programs; regains Nasdaq compliance

MIRA PHARMACEUTICALS, INC.

Acquired 100% of SKNY for restricted MIRA shares; SKNY contributed $5M in marketable securities to MIRA.
Pipeline now includes Ketamir-2 (Phase 1 neuropathic pain), MIRA-55 (oral THC analog), and SKNY-1 (obesity/smoking cessation).
Nasdaq had notified MIRA of stockholders' equity deficiency in April 2025; extension granted to Oct 6, 2025.
After merger closing and ATM sales, MIRA believes it has regained compliance; Nasdaq will continue to monitor.
No specific exchange ratio or deal value disclosed; valuations were independent third-party.

item 1.01item 2.01item 3.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.